文献速递消化系统肿瘤

Temab-A(c-Met抗体偶联药物)在晚期结直肠癌及实体瘤的I期研究

Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
PubMed 文献 · J Clin Oncol · 2026-05-01

该首次人体I期研究评估了新型c-Met抗体偶联药物Temab-A在晚期实体瘤及经治转移性结直肠癌(mCRC)中的安全性、药代动力学和疗效。剂量递增确定3.0 mg/kg每3周为最大耐受剂量;mCRC患者总体客观缓解率为15.6%,疾病控制率74.6%,中位无进展生存期4.6个月,中位总生存期10.4个月。2.4 mg/kg每3周方案安全性可控且具抗肿瘤活性。

要点

  • Temab-A在mCRC中客观缓解率15.6%,疾病控制率74.6%。
  • 推荐II期剂量为2.4 mg/kg每3周,安全性可控。
  • 常见不良事件为胃肠道(78%)和血液学(71%)毒性。

核心结论

  • Temab-A 2.4 mg/kg每3周方案在晚期mCRC中安全性可控,并显示出有前景的抗肿瘤活性。

研究设计与样本

  • 首次人体I期研究(NCT05029882),包括剂量递增和mCRC单药剂量扩展。
  • 剂量递增57例接受Temab-A;mCRC患者共122例(剂量递增29例,随机剂量优化扩展93例)。
  • mCRC扩展纳入确认为BRAF野生型、微卫星稳定/错配修复功能完整的患者,随机分配至1.6、2.4或3.0 mg/kg每3周。

主要发现

  • 剂量递增确定3.0 mg/kg每3周为最大耐受剂量。
  • 所有患者均发生至少1例治疗中出现的不良事件,最常见为胃肠道(78%)和血液学(71%)毒性。
  • 治疗相关停药和死亡分别占10%和3%。
  • mCRC患者总体客观缓解率为15.6%(95%CI 9.6-23.2),疾病控制率74.6%(95%CI 65.9-82.0),缓解持续时间5.9个月(95%CI 4.1-10.5)。
  • 中位无进展生存期4.6个月(95%CI 4.0-5.4),中位总生存期10.4个月(95%CI 8.9-13.1);2.4和3.0 mg/kg剂量组缓解更常见。

关键数值与推荐

  • 推荐II期剂量为2.4 mg/kg每3周。

临床怎么用

  • Temab-A 2.4 mg/kg每3周可作为c-Met靶向ADC在晚期mCRC的后续研究剂量。
  • 治疗期间需重点监测胃肠道和血液学毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The antibody-drug conjugate Temab-A comprises the c-Met-targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan. A first-in-human phase I study (ClinicalTrials.gov identifier: NCT05029882) of Temab-A in patients with advanced solid tumors whose disease has progressed is currently ongoing. We report results from all patients in the dose escalation and the monotherapy metastatic colorectal cancer (mCRC) dose expansion. METHODS: Temab-A was administered intravenously once every 3 weeks as a monotherapy starting at 1.6 mg/kg in dose escalation. In mCRC dose expansion, patients with confirmed BRAF wild-type, microsatellite stable/mismatch repair-proficient mCRC were randomly assigned to 1.6 mg/kg, 2.4 mg/kg, or 3.0 mg/kg Temab-A once every 3 weeks. Primary end points included safety, pharmacokinetics, recommended phase II dose of Temab-A monotherapy, and Temab-A efficacy in patients with mCRC. RESULTS: In total, 57 patients received ≥1 dose of Temab-A in dose escalation; 3.0 mg/kg once every 3 weeks was established as the maximum tolerated dose. Collectively, in dose escalation and dose expansion, 122 patients with mCRC received Temab-A (dose escalation, N = 29; randomized dose optimization expansion, N = 93). All patients experienced ≥1 treatment-emergent adverse event; the most frequent were gastrointestinal (78%) and hematologic (71%) toxicities. Treatment-related discontinuations and deaths were infrequent (10% and 3%, respectively). Across all doses in patients with mCRC, overall response rate was 15.6% (95% CI, 9.6 to 23.2), disease control rate was 74.6% (95% CI, 65.9 to 82.0), and duration of response was 5.9 months (95% CI, 4.1 to 10.5); responses were more frequent at doses of 2.4 mg/kg and 3.0 mg/kg once every 3 weeks. Median progression-free survival was 4.6 months (95% CI: 4.0, 5.4), and median overall survival was 10.4 months (95% CI, 8.9 to 13.1). CONCLUSION: Temab-A at 2.4 mg/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sharma MR, Powderly J, Kuboki Y, et al. Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. J Clin Oncol. 2026. PMID: 42066233. doi:10.1200/JCO-25-01525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。